GlassScriptPhysician profile
Vi A Ngo
NPI 1104307305
$8,756.10
in general payments reported to CMS, 2019-2025
49 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,101 · 2022: $2,408 · 2023: $2,042 · 2024: $1,721 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,880 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,880.10 |
| Education | $366.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,059.52 | 2021-2025 | Erleada, Darzalex, Balversa |
| Astrazeneca Pharmaceuticals LP | $821.92 | 2022-2025 | Tagrisso, Lynparza, Enhertu |
| Amgen INC. | $668.25 | 2021-2023 | Evenity, Prolia, Lumakras |
| Lilly USA, LLC | $621.94 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $602.56 | 2021-2023 | Adcetris |
| Pfizer INC. | $562.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $457.13 | 2021-2025 | |
| Coherus Oncology, INC. | $428.22 | 2022-2025 | Loqtorzi |
| Takeda Pharmaceuticals U.S.A., INC. | $378.32 | 2021-2024 | Ninlaro, Iclusig |
| Progenics Pharmaceuticals, INC. | $347.81 | 2022-2025 | Pylarify |
| Aveo Pharmaceuticals, INC. | $309.01 | 2022-2025 | Fotivda |
| Eisai INC. | $218.33 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $199.97 | 2022-2025 | Keytruda, Lynparza |
| Exelixis INC. | $181.90 | 2023-2024 | Cabometyx |
| Astellas Pharma US INC | $143.61 | 2022-2024 | Xtandi, Padcev |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $140.53 | 2022-2024 | Pomalyst, Reblozyl |
| Glaxosmithkline, LLC. | $132.07 | 2025 | Jemperli, Zejula |
| Rigel Pharmaceuticals, INC. | $125.58 | 2022-2024 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $118.61 | 2023-2025 | Enhertu, Datroway |
| Incyte Corporation | $117.13 | 2022-2025 | Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $108.17 | 2022-2024 | |
| Iovance Biotherapeutics, INC. | $82.43 | 2025 | Amtagvi |
| Pharmaessentia USA Corporation | $74.42 | 2023-2025 | Besremi |
| Mirati Therapeutics, INC. | $73.26 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $72.37 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $62.29 | 2023-2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $60.51 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $52.55 | 2025 | Opdivo |
| Abbvie INC. | $51.63 | 2024 | |
| Taiho Oncology, INC. | $48.79 | 2024-2025 | |
| Kite Pharma, INC. | $46.32 | 2022-2025 | Yescarta |
| Amneal Pharmaceuticals LLC | $29.89 | 2023 | Neulasta, Avastin, Neupogen |
| Genmab U.S., INC. | $28.75 | 2025 | Epkinly |
| Acrotech Biopharma INC. | $27.38 | 2022 | |
| Sobi, INC | $27.28 | 2025 | |
| Genzyme Corporation | $27.24 | 2025 | |
| Karyopharm Therapeutics INC. | $25.75 | 2021 | |
| Caris Mpi, INC. | $25.19 | 2025 | Mi Cancer Seek |
| Accord Healthcare, INC. | $24.62 | 2024 | |
| Genentech USA, INC. | $21.74 | 2023 | Xolair |
| Novocure INC. | $18.94 | 2025 | Optune Lua (Novottf-200t) |
| Epizyme, INC. | $18.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2022 | |
| Mylan Institutional INC. | $16.98 | 2022 | |
| Cti Biopharma Corp. | $16.31 | 2023 | Vonjo |
| Legend Biotech USA INC. | $16.23 | 2025 | Carvykti |
| Adc Therapeutics America, INC. | $15.91 | 2023 | |
| Servier Pharmaceuticals LLC | $15.84 | 2024 | |
| Octapharma USA, INC. | $15.10 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vi Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.